Dyadic announces research and development collaboration agreement with global biopharmaceutical company

Jupiter, fla., feb. 06, 2024 (globe newswire) -- dyadic international, inc. (“dyadic”, “we”, “us”, “our”, or the “company”) (nasdaq: dyai), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using dyadic's c1 filamentous fungal based microbial protein production platform. under the agreement, research and development activities will be funded by the collaborator.
DYAI Ratings Summary
DYAI Quant Ranking